A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer.
about
Radiotherapy for the palliation of painful bone metastasesRadioisotopes for metastatic bone painRadioisotopes for metastatic bone painComparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: a meta-analysis of randomized controlled trialsThe role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancerPercutaneous radiofrequency ablation of painful osseous metastases: a multicenter American College of Radiology Imaging Network trialMolecular mechanisms and treatment of bone metastasis.Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.Radiotherapy for the palliation of painful bone metastases.High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to boneRadium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.WITHDRAWN: Radioisotopes for metastatic bone pain.Prostate cancer: 11. Alternative approaches and the future of treatmentOptimizing bone health and minimizing skeletal morbidity in men with prostate cancerProstate cancer: 10. Palliative care.Treatment with radioactive (89)strontium for patients with bone metastases from prostate cancer.Strontium-89 treatment for prostate cancer bone metastases: does a prostate-specific antigen response predict for improved survival?NCCN Task Force Report: Bone Health in Cancer Care.Palliative radiotherapy in the treatment of skeletal metastases.Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population.Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges.Radium-223 for the treatment of castration-resistant prostate cancer.Metastatic bone disease and tumour-induced hypercalcaemia: treatment options.Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer.Analgesia for patients with advanced disease: 2Castration-resistant prostate cancer: mechanisms, targets, and treatment.Radiopharmaceuticals for the palliation of painful bone metastases.The changing pattern of management for hormone-refractory, metastatic prostate cancer.Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancerBone-targeted agents: preventing skeletal complications in prostate cancer.Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.Multimodality therapy: bone-targeted radioisotope therapy of prostate cancerUpdate in palliative management of hormone refractory cancer of prostate.Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer.Effective use of strontium-89 in osseous metastases.The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases.Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases.Assessing pharmacological interventions for bone metastases: the need for more patient-centered outcomes.
P2860
Q24202597-EE1ACD4A-79F7-4728-A3FB-8FDE458BD694Q24235589-9EA12101-EA4B-4AAB-B0BD-41164A177B80Q24247773-C786630B-A065-497B-B595-0E5D4785A730Q26785658-206F7886-E595-4D98-8237-92C367E71813Q26823733-D6BB90CD-D6CD-4DF3-A931-30A5B69E7641Q28269037-48929123-595A-49CD-8CB2-30E17A86D49FQ30445717-256BE582-640A-47F6-9088-2AED7F0329C5Q30852837-6EC29C35-5460-4688-9ADB-5431118DF09EQ30868320-D1682BDE-0BFB-4973-9B50-737800A09496Q33343008-AA047BCC-21F7-41A0-9094-57AC8C3DAB24Q33405335-6F3A1D13-2CB5-4603-A3DB-4825C779AA02Q33408024-23798F44-4DBA-4E19-BBE3-154410B90B73Q33440341-FED9F1AE-15E8-47D5-8DD1-15B528568190Q33542346-980B54B0-6962-4B10-9A4E-287337B9AC30Q34023510-58432755-52FF-47B6-9575-D565D73629F9Q34030661-C3A79049-80B6-4EF6-8882-90219D7B6C99Q34078565-8B9116E8-9E75-44D3-A19C-7C27072F7A52Q34190430-08856D0F-4992-4CB1-8035-452636E7F91CQ34617936-7685A97E-43E7-4C82-BBC3-22892374D0B3Q34771930-4F0258CB-2FCB-4F73-A778-63EACE6CB9DFQ35114920-47899085-9DA0-4EE0-94EF-06756E783D1BQ35143943-67F109C7-08B5-437A-8E2F-950E2966A70EQ35653986-A66B98E9-C2E6-4BE4-B70E-B9B58750B4D2Q35668817-9BEC0290-831C-41CD-9746-A8570A114CB2Q35743202-BED50344-C377-4AA8-AD9B-9CB67211D9F7Q35745100-5F75ECAC-E169-4856-BEC1-262789A763C0Q35864027-F6EC235C-7002-4171-935E-E15C4792B95AQ36057121-810A1A07-D4DD-44FD-A180-4AB2837E4698Q36519880-5C4C196C-A9FD-4635-8C11-E35211BD9583Q36622555-412CBD8A-2E7F-4739-8ACA-FA40AF09CD7FQ37039594-46FA188C-17A6-4D21-A1C0-47547EDD53B3Q37166534-357DA22B-600F-48CC-B637-6F9C648A95E9Q37187646-4474DF52-19BB-4194-B95F-A38F3026426FQ37193613-2D35736B-04E3-4E28-A0B7-92F59C2A921DQ37579073-9042BF7C-5E01-4481-99B0-895E9B8632E5Q37720488-8EFEC383-70F5-482D-B23C-782C2CD3E230Q37967436-7D0D4F55-D2C4-4694-AD3D-9F5227152B87Q38001275-9FAFBCB8-E536-40C9-AA9F-DCBB3BC9CC8CQ38004275-BDEBDFA0-3020-4502-AFCA-36D3C601C018Q38018675-43C425AF-7A63-4816-B433-A9926B59CBDD
P2860
A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
A comparison of the palliative ...... in metastatic prostate cancer.
@en
A comparison of the palliative ...... in metastatic prostate cancer.
@nl
type
label
A comparison of the palliative ...... in metastatic prostate cancer.
@en
A comparison of the palliative ...... in metastatic prostate cancer.
@nl
prefLabel
A comparison of the palliative ...... in metastatic prostate cancer.
@en
A comparison of the palliative ...... in metastatic prostate cancer.
@nl
P2093
P1476
A comparison of the palliative ...... in metastatic prostate cancer.
@en
P2093
Dearnaley DP
Lewington VJ
Russell JM
P356
10.1016/0167-8140(94)90411-1
P577
1994-04-01T00:00:00Z